Résultats de 132 patients atteints d'une tumeur pulmonaire traités par cyberknife®

From November 29, 2006 to November 21, 2009, 132 patients with primary pulmonary tumors were treated with Cyberknife ^®. It was either primitive lung tumors classified T1-T2 N0 M0 or secondary tumors of a primitive controlled or slow evolution. 93 men and 39 women. A unique fiducial was inserted in the lung. The average dose was 60 Gy (median 60, [27-75]). The median follow-up was 151 days (7-351 days). The median follow-up was 151 days (7-351 days). The number of distant recurrence was 62 (46.97%) of which 31 (23.48%) died. The number of local recurrence was 18 (13.64%), 8 (6.06%) died. The average dose was 60 Gy (median 60, [27-75]). Three patients were treated with a single fraction, 78 fractions with 3, 4 with 5 and 42 fractions with 5 fractions. The Cyberknife ^® is an effective treatment for primary or secondary lung tumors. The Cyberknife ^® is an effective treatment for primary or secondary lung tumors. The use of a unique fiducial has reduced the risk of complications during installation without damaging the local control rate was excellent (13.6% at one year and a half).